Large Differences between Focal and Diffuse Patterns of Stable CAD

PCI is far more successful at reducing ischemia when treating focal stable coronary artery disease (CAD). However, there were no differences in symptoms between both types of CAD. 

Grandes diferencias entre angioplastia en enfermedad focal vs difusa

Physiological assessment with pressure wire pullback can be used to distinguish focal vs diffuse CAD, even though the relevance of this distinction has not been looked at closely. 

Using the ORBITA database, researchers tested PCI efficacy against placebo in both types of CAD patterns (focal vs diffuse). They observed the impact of these patterns on stress echocardiography ischemia and symptom end points. 

164 patients were assessed with iFR pullback before randomization. Focal CAD was defined as iFR drop >0.03 within 15 mm. Greater distances were defined as diffuse CAD. 

Of the 85 patients in the ORBITA PCI branch, 48 showed focal lesions and 37 diffuse CAD. IN the placebo arm (n=79) 35 had focal lesions and 44 diffuse CAD.

Focal stenosis was associated with significantly lower FFR and iFR vs. diffuse pattern patients (mean FFR and iFR, focal 0.60±0.15 and 0.65±0.24, diffuse 0.78±0.10 and 0.88±0.08, respectively, p<0.0001).


Read also: New Markers of Aortic Stenosis Define Asymptomatic Patients.


Stress echocardiography ischemia saw significantly greater reduction with PCI when patients showed a focal pattern, vs. a diffuse pattern (p<0.05). 

PCI did not show significant variation in exercise time pre and post randomization. This continued to be true after stratifying patients according to CAD pattern. 

PCI was superior to placebo when using the Seattle Angina Questionnaire both in frequency and freedom from symptoms. However, these differences continued to be true and similar when stratifying patients into focal and diffuse CAD. 

Conclusion

PCI achieve greater ischemia reduction with focal CAD vs. diffuse. There were no differences in symptom end points. 

CIRCINTERVENTIONS-120-009891

Original Title: Placebo-Controlled Efficacy of Percutaneous Coronary Intervention for Focal and Diffuse Patterns of Stable Coronary Artery Disease.

Reference: Christopher A Rajkumar et al. Circ Cardiovasc Interv. 2021 Aug 3;CIRCINTERVENTIONS120009891. Online ahead of print. doi: 10.1161/CIRCINTERVENTIONS.120.009891.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....